lactic acid and HIV Infections studies

Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.

HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).

Research Excerpts

Excerpt	Relevance	Reference
" However, their ability to inhibit polymerase-γ has been associated with several mitochondrial toxicities, including potentially life-threatening lactic acidosis."	9.16	Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial. ( Bussmann, H; D'Aquila, RT; DeGruttola, V; Eden, SK; Essex, M; Hendrickson, SL; Marlink, RG; Novitsky, V; O'Brien, SJ; Samuels, DC; Shepherd, BE; Wester, CW; Winkler, CA, 2012)
" The preliminary data from this pilot study suggest that l-carnitine may be helpful for patients who have nucleoside-analog-related lactic acidosis with blood lactate levels >10 mmol/L."	9.10	Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. ( Azoulay, E; Branche, F; Cariou, A; Claessens, YE; Dhainaut, JF; Goldgran-Toledano, D; Monchi, M; Rouges, P; Soufir, L, 2003)
"Hyperlactataemia/lactic acidosis was associated with exposure to dideoxynucleosides, female gender, advanced immunosuppression and possibly ethnicity."	8.84	Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. ( , 2007)
"Nucleoside reverse-transcriptase inhibitors (NRTIs) have been associated with functional and structural mitochondrial abnormalities, leading to several adverse events, such as increased serum lactic acid levels and lactic acidosis."	8.82	Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. ( Calza, L; Chiodo, F; Manfredi, R, 2005)
" NRTIs can induce mitochondrial impairment that leads to a number of adverse events, including symptomatic lactic acidosis."	8.82	Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors. ( Cariou, A; Chiche, JD; Claessens, YE; Mira, JP, 2003)
"Studies of injectable poly-L-lactic acid (PLLA) in human immunodeficiency virus (HIV)-associated facial lipoatrophy have predominantly included male Caucasians."	7.78	Injectable poly-L-lactic acid for human immunodeficiency virus-associated facial lipoatrophy: cumulative year 2 interim analysis of an open-label study (FACES). ( Bassichis, B; Blick, G; Conant, M; Condoluci, D; Daro-Kaftan, E; Echavez, M; Eviatar, J; Gold, MH; Hamilton, T; Hanke, CW; Humble, G; LaMarca, A; Mest, D; Pierone, G, 2012)
"Hyperlactatemia and lactic acidosis (LA) are among the most dangerous and life-threatening side effect that occurs during therapy with some nucleoside reverse transcriptase inhibitors (NRTIs), mainly didanosine (ddI) and stavudine (d4T), also known as d-drugs."	7.78	The role of nucleoside reverse transcriptase inhibitors usage in the incidence of hyperlactatemia and lactic acidosis in HIV/AIDS patients. ( Dragovic, G; Jevtovic, D, 2012)
"Lactic acidosis (LA) and severe hyperlactataemia (HL) are infrequent but serious complications of antiretroviral therapy that have been associated with a high fatality rate."	7.77	Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis. ( Arenas-Pinto, A; Bhaskaran, K; Carr, A; Copas, A; Dunn, D; Grant, A; Hoy, J; Martinez, E; Reiss, P; Weber, R; Weller, I; Worm, SW, 2011)
"The combination of highly active antiretroviral therapy (HAART) plus ribavirin (RBV) in patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection has been reported to cause mitochondrial toxicity (MT)."	7.76	Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. ( Breitenecker, F; Gangl, A; Kosi, L; Maresch, J; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Wrba, F, 2010)
"HIV-patients receiving nucleoside reverse transcriptase inhibitors (NRTIs), hospitalized with lactic acidosis or symptomatic hyperlactatemia."	7.73	[Treatment of symptomatic hyperlactatemia and lactic acidosis in HIV+ patients under nucleoside reverse transcriptase inhibitors]. ( Deig, E; Garrabou, G; Miró, O; Pedrol, E; Ribell, M; Soler, A; Villà, Mdel C, 2005)
"Lactic acidosis is a life-threatening complication of antiretroviral therapy with an incidence of about 1% per year."	7.72	[Lactic acidosis in HIV-patients--diagnosis and treatment]. ( Walker, UA, 2004)
"Lactic acidosis has been reported as a complication associated with antiretroviral therapy; in particular, usually with use of nucleoside reverse-transcriptase inhibitors."	7.72	Human immunodeficiency virus infection with human granulocytic ehrlichiosis complicated by symptomatic lactic acidosis. ( Altice, FL; Springer, SA, 2003)
" Raised lactate represents part of a spectrum of lactate and acid-base disturbance that infrequently includes lactic acidosis."	7.71	Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. ( Asboe, D; Datta, D; Gazzard, BG; Mandalia, S; Morlese, J; Moyle, GJ, 2002)
" Forty patients were evaluated for adverse events (bruising, edema, erythema, subcutaneous papules) and satisfaction."	5.36	Modified poly-L-lactic acid injection technique: safety and efficacy of "cross-fanning" in non-HIV-related facial atrophy. ( Lee, JY; Schulman, MR; Skolnik, RA, 2010)
" polylactic acid (PLA) for the treatment of facial lipoatrophy in HIV-infected adults."	5.17	Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE]. ( Bouchaud, O; Carbonnel, E; Dolivo, M; Girard, PM; Lafaurie, M; Loze, B; Madelaine, I; May, T; Molina, JM; Porcher, R, 2013)
" However, their ability to inhibit polymerase-γ has been associated with several mitochondrial toxicities, including potentially life-threatening lactic acidosis."	5.16	Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial. ( Bussmann, H; D'Aquila, RT; DeGruttola, V; Eden, SK; Essex, M; Hendrickson, SL; Marlink, RG; Novitsky, V; O'Brien, SJ; Samuels, DC; Shepherd, BE; Wester, CW; Winkler, CA, 2012)
" The preliminary data from this pilot study suggest that l-carnitine may be helpful for patients who have nucleoside-analog-related lactic acidosis with blood lactate levels >10 mmol/L."	5.10	Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. ( Azoulay, E; Branche, F; Cariou, A; Claessens, YE; Dhainaut, JF; Goldgran-Toledano, D; Monchi, M; Rouges, P; Soufir, L, 2003)
"Fatal lactic acidosis is a serious complication of therapy with nucleoside analogues."	5.09	Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. ( Amiel, C; De La Tribonnière, X; Dhennain, C; Gérard, Y; Maulin, L; Maurage, CA; Mouton, Y; Robin, S; Sablonnière, B; Yazdanpanah, Y, 2000)
"Hyperlactataemia/lactic acidosis was associated with exposure to dideoxynucleosides, female gender, advanced immunosuppression and possibly ethnicity."	4.84	Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. ( , 2007)
" Suspected antiretroviral toxicities meeting these criteria include: HIV-associated lipodystrophy which can include peripheral lipoatrophy, lipohypertrophy and metabolic abnormalities; hyperlactatemia and lactic acidosis; and metabolic bone abnormalities such as decreased bone mineral density, osteoporosis and osteonecrosis."	4.82	Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection. ( Bondy, G; Heath, KV; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Singer, J, 2003)
" NRTIs can induce mitochondrial impairment that leads to a number of adverse events, including symptomatic lactic acidosis."	4.82	Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors. ( Cariou, A; Chiche, JD; Claessens, YE; Mira, JP, 2003)
"Nucleoside reverse-transcriptase inhibitors (NRTIs) have been associated with functional and structural mitochondrial abnormalities, leading to several adverse events, such as increased serum lactic acid levels and lactic acidosis."	4.82	Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. ( Calza, L; Chiodo, F; Manfredi, R, 2005)
"Hyperlactatemia and lactic acidosis (LA) are among the most dangerous and life-threatening side effect that occurs during therapy with some nucleoside reverse transcriptase inhibitors (NRTIs), mainly didanosine (ddI) and stavudine (d4T), also known as d-drugs."	3.78	The role of nucleoside reverse transcriptase inhibitors usage in the incidence of hyperlactatemia and lactic acidosis in HIV/AIDS patients. ( Dragovic, G; Jevtovic, D, 2012)
"Studies of injectable poly-L-lactic acid (PLLA) in human immunodeficiency virus (HIV)-associated facial lipoatrophy have predominantly included male Caucasians."	3.78	Injectable poly-L-lactic acid for human immunodeficiency virus-associated facial lipoatrophy: cumulative year 2 interim analysis of an open-label study (FACES). ( Bassichis, B; Blick, G; Conant, M; Condoluci, D; Daro-Kaftan, E; Echavez, M; Eviatar, J; Gold, MH; Hamilton, T; Hanke, CW; Humble, G; LaMarca, A; Mest, D; Pierone, G, 2012)
"Perinatal antiretroviral (ARV) exposure has been related to hyperlactatemia and lactic acidosis in infants born to HIV-infected mothers."	3.78	Hyperlactatemia and in utero exposure to antiretrovirals: is the control group the clue? ( Arranz, JA; Espiau, M; Figueras, C; Martín-Nalda, A; Martínez-Gómez, X; Melendo, S; Riudor, E; Soler-Palacín, P, 2012)
"Lactic acidosis (LA) and severe hyperlactataemia (HL) are infrequent but serious complications of antiretroviral therapy that have been associated with a high fatality rate."	3.77	Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis. ( Arenas-Pinto, A; Bhaskaran, K; Carr, A; Copas, A; Dunn, D; Grant, A; Hoy, J; Martinez, E; Reiss, P; Weber, R; Weller, I; Worm, SW, 2011)
"The combination of highly active antiretroviral therapy (HAART) plus ribavirin (RBV) in patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection has been reported to cause mitochondrial toxicity (MT)."	3.76	Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. ( Breitenecker, F; Gangl, A; Kosi, L; Maresch, J; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Wrba, F, 2010)
"Female gender should be carefully monitored with respect to their clinical, laboratory and biological data to diminish the occurrence of lactic acidosis."	3.74	Co-factors for abnormal lactate levels among persons with HIV disease at a tertiary HIV care setting in South India. ( Balakrishnan, P; Deepak, M; Kumarasamy, N; Murugavel, KG; Shankar, EM; Solomon, S; Srinivas, CN; Sundaram, M, 2008)
"HIV-patients receiving nucleoside reverse transcriptase inhibitors (NRTIs), hospitalized with lactic acidosis or symptomatic hyperlactatemia."	3.73	[Treatment of symptomatic hyperlactatemia and lactic acidosis in HIV+ patients under nucleoside reverse transcriptase inhibitors]. ( Deig, E; Garrabou, G; Miró, O; Pedrol, E; Ribell, M; Soler, A; Villà, Mdel C, 2005)
" Lactic acidosis was diagnosed in 4 of 1566 persons, all of whom were receiving stavudine and didanosine."	3.73	Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? ( Günthard, HF; Haupts, S; Imhof, A; Ledergerber, B; Weber, R, 2005)
" Only one case experienced lactic acidosis and died during follow-up."	3.72	Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients. ( Alberti, C; Bagnard, G; Carel, O; Erlich, D; Feugeas, JP; Hocqueloux, L; Lafaurie, M; Lukasiewicz, E; Molina, JM, 2003)
"Lactic acidosis is a feared side effect of nucleoside analog treatment, one of the cornerstones in the management of HIV infection."	3.72	Preanalytical handling of samples for measurement of plasma lactate in HIV patients. ( Andersen, O; Haugaard, SB; Iversen, J; Jørgensen, LT; Madsbad, S; Nielsen, JO; Sørensen, S, 2003)
"Lactic acidosis has been reported as a complication associated with antiretroviral therapy; in particular, usually with use of nucleoside reverse-transcriptase inhibitors."	3.72	Human immunodeficiency virus infection with human granulocytic ehrlichiosis complicated by symptomatic lactic acidosis. ( Altice, FL; Springer, SA, 2003)
"Lactic acidosis is a life-threatening complication of antiretroviral therapy with an incidence of about 1% per year."	3.72	[Lactic acidosis in HIV-patients--diagnosis and treatment]. ( Walker, UA, 2004)
"Most (85%) women received highly active antiretroviral therapy (HAART) during pregnancy (mean duration: 31 weeks) and zidovudine during labor (93%)."	3.72	Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. ( Artuch, R; Fortuny, C; Jimenez, R; Muñoz-Almagro, C; Noguera, A; Pou, J; Sanchez, E; Vilaseca, MA, 2004)
"Hyperlactatemia and lactic acidosis occur in HIV-infected adults receiving antiretroviral treatment."	3.72	Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. ( Artuch, R; Fortuny, C; Jiménez, R; Muñoz-Almagro, C; Noguera, A; Pou, J; Sanchez, E; Vilaseca, MA, 2003)
"Lactic acidosis in patients infected with the human immunodeficiency virus was initially identified as a rare complication of therapy with nucleoside analog reverse transcriptase inhibitors (NRTIs)."	3.72	Lactic acidemia in infection with human immunodeficiency virus. ( Carr, A, 2003)
"Lactic acidosis is a life-threatening event during antiretroviral therapy (ART)."	3.72	Matched case-control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapy. ( Datta, D; Gazzard, B; Mandalia, S; Moyle, G, 2003)
" Raised lactate represents part of a spectrum of lactate and acid-base disturbance that infrequently includes lactic acidosis."	3.71	Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. ( Asboe, D; Datta, D; Gazzard, BG; Mandalia, S; Morlese, J; Moyle, GJ, 2002)
" mtDNA depletion may contribute to lactic acidosis, steatohepatitis and liver failure."	3.71	Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. ( Setzer, B; Venhoff, N; Walker, UA, 2002)
"Long-term treatment with nucleoside reverse transcriptase inhibitors (NRTIs) can induce mitochondrial dysfunction, most severely represented by lactic acidosis."	3.71	Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment. ( Brinkman, K; Frissen, PH; Regez, RM; Smulders, YM; Treskes, M; Troost, N; Vrouenraets, SM; Weigel, HM, 2002)
" Lactic acidosis, characterized by metabolic acidosis, blood lactate above 5 mmol/l, hepatic steatosis and high mortality, represents the extreme end of this spectrum where there is complete decompensation."	3.71	Hyperlactatemia syndromes in people with HIV infection. ( John, M; Mallal, S, 2002)
"In 516 patient-years of observation, two patients experienced severe fulminant lactic acidosis (lactate > 5 mmol/l) and hepatic steatosis attributable to nucleoside analogue reverse transcriptase inhibitors (NRTI)."	3.71	Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. ( James, IR; John, M; Mallal, SA; McKinnon, EJ; Moore, CB; Nolan, D; Upton, RP, 2001)
" An OGTT was performed in 30 subjects: 16 HIV-infected treated patients without adverse events (group 1) and 14 HIV-infected patients with adverse events related to nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity (group 2)."	2.73	Oral glucose loading for detection of mitochondrial toxicity during HAART in HIV-infected patients. ( Borm, GF; Koopmans, PP; ter Hofstede, HJ, 2007)
"Treatment interruptions in patients with nadir CD4 counts of >350 cells/microL seem safe for at least 48 weeks."	2.72	Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/microL: a randomized trial. ( Bouzas, MB; Cahn, P; Cassetti, I; Gun, A; Iannella, Mdel C; Krolewiecki, AJ; Pérez, H; Valiente, J; Vanzulli, C; Zala, C, 2006)
"Vaginal microbiota and sexually transmitted infections (STIs) are likely to influence the transmission of cell-associated human immunodeficiency virus (HIV)."	2.50	Vaginal microbiota and sexually transmitted infections that may influence transmission of cell-associated HIV. ( Cone, RA, 2014)
"Lactic acid (LA) is a major organic acid metabolite produced by vaginal lactobacilli that elicits anti-inflammatory effects from cervicovaginal epithelial cells and is dramatically depleted during BV."	1.51	Distinct Immune Responses Elicited From Cervicovaginal Epithelial Cells by Lactic Acid and Short Chain Fatty Acids Associated With Optimal and Non-optimal Vaginal Microbiota. ( Delgado-Diaz, DJ; Gugasyan, R; Hayward, JA; Hearps, AC; Tachedjian, G; Tyssen, D, 2019)
" Higher intracellular drug concentration was measured for cells dosed with the triple ARV-NP combination compared to the equivalent unformulated drugs."	1.42	Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission. ( Bever, AM; Blakney, AK; Bright, DK; Cao, S; Jiang, Y; Suydam, IT; Woodrow, KA, 2015)
"This study demonstrated, in real-life conditions and on a large sample, that PLLA injections were feasible, efficient, and safe when performed by trained physicians."	1.40	Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. ( Chassany, O; Christen, MO; Dolivo, M; Duracinsky, M; Goujard, C; Herrmann, S; Leclercq, P, 2014)
"Glycogen levels were significantly lower in both rhesus (median=0."	1.38	A comparison of lower genital tract glycogen and lactic acid levels in women and macaques: implications for HIV and SIV susceptibility. ( Gilbert, D; Kendrick, SR; Mirmonsef, P; Spear, GT; Veazey, RS; Wang, J, 2012)
"ARV use during pregnancy has resulted in a dramatic decrease in mother-to-child transmission of HIV, and the risk of elevated lactate in HEU children is low."	1.37	Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medications. ( Crain, MJ; Griner, R; Mofenson, LM; Read, JS; Rich, KC; Tassiopoulos, K; Williams, PL, 2011)
"Pediatric medication dosing and administration, faced with inherent challenges of dose to body weight adjustment and variable delivery vehicles, may lead to inadvertent errors effectively resulting in overdose."	1.37	Zidovudine (AZT) overdose in a healthy newborn receiving postnatal prophylaxis. ( Esteban-Cruciani, N; Hoffman, RS; Lee, S; Livshits, Z; Nelson, LS, 2011)
" Forty patients were evaluated for adverse events (bruising, edema, erythema, subcutaneous papules) and satisfaction."	1.36	Modified poly-L-lactic acid injection technique: safety and efficacy of "cross-fanning" in non-HIV-related facial atrophy. ( Lee, JY; Schulman, MR; Skolnik, RA, 2010)
" Recent evidence shows that local/regional/systemic delayed adverse effects may appear with its use."	1.35	Late-onset immune-mediated adverse effects after poly-L-lactic acid injection in non-HIV patients: clinical findings and long-term follow-up. ( Alijotas-Reig, J; Garcia-Gimenez, V; Vilardell-Tarres, M, 2009)
" Periodic monitoring for adverse reactions and degree of improvement were assessed by the patient, the treating physician, and a non-treating physician."	1.33	Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. ( Burgess, CM; Quiroga, RM, 2005)
"Lactate levels were higher in patients with presumed NRTI-related adverse events."	1.32	Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers. ( Koopmans, PP; ter Hofstede, HJ; Willems, HL, 2004)
"Osteopenia has been associated with antiretroviral therapy, particularly with protease inhibitors."	1.31	Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. ( Carr, A; Cooper, DA; Eisman, JA; Miller, J, 2001)
"Nucleoside analogues can induce toxic effects on mitochondria by inhibiting the human DNA polymerase gamma."	1.31	Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. ( Alexander, CS; Brumme, ZL; Côté, HC; Craib, KJ; Harrigan, PR; Harris, M; Montaner, JS; O'Shaughnessy, MV; Ting, L; Wong, H; Wynhoven, B, 2002)

Research

Studies (150)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Facial Volume Score

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.67)	18.2507
2000's	108 (72.00)	29.6817
2010's	41 (27.33)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Delgado-Diaz, DJ	1
Tyssen, D	2
Hayward, JA	1
Gugasyan, R	2
Hearps, AC	2
Tachedjian, G	2
Srbinovski, D	1
Bayigga, L	1
Diaz, DJD	1
Aldunate, M	1
Cone, RA	2
Anderson, DJ	1
Kozić, D	1
Bjelan, M	1
Boban, J	1
Ostojić, J	1
Turkulov, V	1
Todorović, A	1
Lemajić-Komazec, S	1
Brkić, S	1
Duracinsky, M	2
Leclercq, P	2
Armstrong, AR	1
Dolivo, M	4
Mouly, F	1
Chassany, O	2
Lafaurie, M	3
Girard, PM	1
May, T	1
Bouchaud, O	1
Carbonnel, E	1
Madelaine, I	2
Loze, B	1
Porcher, R	2
Molina, JM	3
Liu, K	1
Sun, Y	1
Liu, D	1
Yin, J	1
Qiao, L	1
Shi, Y	1
Dong, Y	1
Li, N	1
Zhang, F	1
Chen, D	1
Chaowanachan, T	1
Krogstad, E	1
Ball, C	1
Woodrow, KA	2
van Ramshorst, MS	1
Struthers, HE	1
McIntyre, JA	1
Peters, RP	1
Alves, GN	1
Tavares, AM	1
Vieira, PJ	1
Sprinz, E	1
Ribeiro, JP	1
Almeida, SM	1
Marquie-Beck, J	1
Bhatt, A	1
Letendre, S	1
McCutchan, A	1
Ellis, R	2
Herrmann, S	1
Christen, MO	1
Goujard, C	1
Climent, N	2
Munier, S	1
Piqué, N	1
García, F	2
Pavot, V	2
Primard, C	1
Casanova, V	1
Gatell, JM	3
Verrier, B	2
Gallart, T	1
Gu, J	1
Yang, S	1
Ho, EA	1
Subbarao, S	1
Wilkinson, KA	1
van Halsema, CL	1
Rao, SS	1
Boyles, T	1
Utay, NS	1
Wilkinson, RJ	1
Meintjes, G	1
Gous, NM	1
Scott, LE	1
Potgieter, J	1
Ntabeni, L	1
Sanne, I	1
Stevens, WS	1
Jiang, Y	1
Cao, S	1
Bright, DK	1
Bever, AM	1
Blakney, AK	1
Suydam, IT	1
Rochereau, N	1
Genin, C	1
Tiraby, G	1
Vernejoul, F	1
Perouzel, E	1
Lioux, T	1
Paul, S	1
Destache, CJ	4
Mandal, S	1
Yuan, Z	1
Kang, G	1
Date, AA	4
Lu, W	1
Shibata, A	4
Pham, R	1
Bruck, P	1
Rezich, M	1
Zhou, Y	2
Vivekanandan, R	1
Fletcher, CV	1
Li, Q	1
Srinivasan, P	1
Zhang, J	1
Martin, A	1
Kelley, K	1
McNicholl, JM	1
Buckheit, RW	1
Smith, JM	1
Ham, AS	1
Ghosh, S	2
Mondal, L	1
Chakraborty, S	1
Mukherjee, B	2
Rudd, KE	1
Tutaryebwa, LK	1
West, TE	1
Sundaram, M	1
Srinivas, CN	1
Shankar, EM	1
Deepak, M	1
Murugavel, KG	1
Balakrishnan, P	1
Solomon, S	1
Kumarasamy, N	1
Fabian, J	1
Venter, WD	1
Mkhabela, L	1
Levin, JB	1
Baker, L	1
Naicker, S	1
Roca, B	1
Gingelmaier, A	1
Grubert, TA	1
Kost, BP	1
Setzer, B	3
Lebrecht, D	2
Mylonas, I	1
Mueller-Hoecker, J	1
Jeschke, U	1
Hiedl, S	1
Friese, K	1
Walker, UA	5
Lai, SK	1
Hida, K	1
Shukair, S	1
Wang, YY	1
Figueiredo, A	1
Cone, R	1
Hope, TJ	1
Hanes, J	1
Hilton, S	1
Narciso, P	1
Bucciardini, R	1
Tozzi, V	1
Bellagamba, R	1
Ivanovic, J	1
Giulianelli, M	1
Scevola, S	1
Palummieri, A	1
Fragola, V	1
Massella, M	1
Fracasso, L	1
De Vita, R	1
Pierro, P	1
Del Maestro, A	1
Mirra, M	1
Weimer, L	1
Alijotas-Reig, J	1
Garcia-Gimenez, V	1
Vilardell-Tarres, M	1
Belgum, T	1
Christensen, K	1
Sharma, A	1
Dash, A	1
Lee, JY	1
Schulman, MR	1
Skolnik, RA	1
Reiberger, T	1
Kosi, L	1
Maresch, J	1
Breitenecker, F	1
Payer, BA	1
Wrba, F	1
Rieger, A	1
Gangl, A	1
Peck-Radosavljevic, M	1
de Almeida, SM	1
Boritza, K	1
Cogo, LL	1
Pessa, L	1
França, J	1
Rota, I	1
Muro, M	1
Ribeiro, C	1
Raboni, SM	1
Vidal, LR	1
Nogueira, MB	1
Arenas-Pinto, A	1
Grant, A	1
Bhaskaran, K	1
Copas, A	1
Carr, A	4
Worm, SW	1
Martinez, E	2
Reiss, P	1
Dunn, D	1
Weber, R	2
Hoy, J	1
Weller, I	1
Leung, L	1
Wilson, D	1
Manini, AF	1
Mirmonsef, P	1
Gilbert, D	1
Veazey, RS	1
Wang, J	1
Kendrick, SR	1
Spear, GT	1
Zhang, T	1
Sturgis, TF	1
Youan, BB	1
Livshits, Z	1
Lee, S	1
Hoffman, RS	1
Nelson, LS	1
Esteban-Cruciani, N	1
Soler-Palacín, P	1
Martín-Nalda, A	1
Martínez-Gómez, X	1
Melendo, S	1
Riudor, E	1
Arranz, JA	1
Espiau, M	1
Figueras, C	1
Crain, MJ	1
Williams, PL	1
Griner, R	1
Tassiopoulos, K	1
Read, JS	1
Mofenson, LM	1
Rich, KC	1
Wobeser, W	1
Morgan, E	1
Rumman, A	1
Ford, PM	1
Wester, CW	1
Eden, SK	1
Shepherd, BE	1
Bussmann, H	1
Novitsky, V	1
Samuels, DC	1
Hendrickson, SL	1
Winkler, CA	1
O'Brien, SJ	1
Essex, M	1
D'Aquila, RT	1
DeGruttola, V	1
Marlink, RG	1
Pattnaik, G	1
Sinha, B	1
Basak, S	1
Mondal, S	1
Bera, T	1
Dragovic, G	1
Jevtovic, D	1
Bassichis, B	1
Blick, G	1
Conant, M	2
Condoluci, D	1
Echavez, M	1
Eviatar, J	1
Gold, MH	1
Hamilton, T	1
Hanke, CW	1
Humble, G	1
LaMarca, A	1
Daro-Kaftan, E	1
Mest, D	1
Pierone, G	1
Jones, DH	1
Goede, M	2
Sanford, B	2
La Bruzzo, K	1
Belshan, M	2
McMullen, E	1
Pham, A	1
Waiswa, M	1
Byarugaba, BB	1
Ocama, P	2
Mayanja-Kizza, H	2
Seremba, E	1
Ganguli, S	1
Crowther, M	1
Colebunders, R	1
Chariot, P	1
Bourokba, N	1
Brivet, F	1
Rastegar, DA	1
Casademont, J	2
Miró, O	3
Cardellach, F	2
Moyle, GJ	2
Datta, D	2
Mandalia, S	3
Morlese, J	1
Asboe, D	1
Gazzard, BG	1
Moyle, G	2
Tesiorowski, AM	1
Harris, M	5
Chan, KJ	1
Thompson, CR	1
Montaner, JS	6
Venhoff, N	1
Schambelan, M	2
Benson, CA	1
Currier, JS	1
Dubé, MP	1
Gerber, JG	1
Grinspoon, SK	1
Grunfeld, C	1
Kotler, DP	1
Mulligan, K	2
Powderly, WG	1
Saag, MS	1
Vittecoq, D	1
Jardel, C	2
Barthélémy, C	1
Escaut, L	1
Cheminot, N	1
Chapin, S	1
Sternberg, D	1
Maisonobe, T	1
Lombès, A	2
Huff, B	1
Heath, KV	1
Bondy, G	1
Singer, J	1
O'Shaughnessy, MV	3
Hogg, RS	2
Lichterfeld, M	1
Fischer, HP	1
Spengler, U	1
Rockstroh, JK	1
Hocqueloux, L	1
Alberti, C	1
Feugeas, JP	1
Lukasiewicz, E	1
Bagnard, G	1
Carel, O	1
Erlich, D	1
Antoniou, T	1
Weisdorf, T	1
Gough, K	1
Vrouenraets, SM	1
Treskes, M	1
Regez, RM	1
Troost, N	1
Smulders, YM	1
Weigel, HM	1
Frissen, PH	1
Brinkman, K	2
Zala, C	2
Ochoa, C	1
Tocci, M	1
Quercia, R	1
Mittelman, G	1
Perez, H	2
Cahn, P	2
Claessens, YE	2
Cariou, A	2
Monchi, M	1
Soufir, L	1
Azoulay, E	1
Rouges, P	1
Goldgran-Toledano, D	1
Branche, F	1
Dhainaut, JF	1
Otten, G	1
Schaefer, M	1
Greer, C	1
Calderon-Cacia, M	1
Coit, D	1
Kazzaz, J	1
Medina-Selby, A	1
Selby, M	1
Singh, M	1
Ugozzoli, M	1
zur Megede, J	1
Barnett, SW	1
O'Hagan, D	1
Donnelly, J	1
Ulmer, J	1
Chiche, JD	1
Mira, JP	1
Miura, T	1
Goto, M	1
Hosoya, N	1
Odawara, T	1
Kitamura, Y	1
Nakamura, T	1
Iwamoto, A	1
Springer, SA	1
Altice, FL	1
Noguera, A	2
Fortuny, C	2
Sanchez, E	2
Artuch, R	2
Vilaseca, MA	2
Muñoz-Almagro, C	2
Pou, J	2
Jiménez, R	2
Alimenti, A	1
Burdge, DR	1
Ogilvie, GS	1
Money, DM	1
Forbes, JC	1
Gazzard, B	1
Andersen, O	4
Haugaard, SB	4
Jørgensen, LT	1
Sørensen, S	1
Nielsen, JO	2
Madsbad, S	3
Iversen, J	3
Valantin, MA	2
Aubron-Olivier, C	1
Ghosn, J	2
Laglenne, E	1
Pauchard, M	1
Schoen, H	1
Bousquet, R	1
Katz, P	1
Costagliola, D	2
Katlama, C	2
ter Hofstede, HJ	2
Willems, HL	1
Koopmans, PP	2
Bäuerle, J	1
Laguno, M	1
Murillas, J	1
Mauss, S	1
Schmutz, G	1
Miquel, R	1
Mallolas, J	1
Côté, HC	2
Yip, B	1
Harrigan, PR	2
Lysakova, L	1
Brown, S	1
Sibtain, N	1
Healy, J	1
Priest, C	1
Barton, SE	2
Milazzo, L	1
Riva, A	1
Sangaletti, O	1
Piazza, M	1
Antinori, S	1
Moroni, M	1
Onesti, MG	1
Renzi, LF	1
Paoletti, F	1
Scuderi, N	1
Bauer, AM	1
Sternfeld, T	1
Horster, S	1
Schunk, M	1
Goebel, FD	2
Bogner, JR	1
Perry, CM	1
Godfried, MH	1
Boer, K	1
Beuger, S	1
Scherpbier, HJ	1
Kuijpers, TW	1
Calza, L	2
Manfredi, R	2
Chiodo, F	2
Burgess, CM	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Randomized, Comparative, Multicenter, Patient-blinded Trial of the Safety and Efficacy of Intradermal Injections of Polylactic Acid (Newfill TM) Versus Polyacrylamid Gel (Eutrophill) in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132[NCT00383734]	Phase 3	148 participants (Actual)	Interventional	2006-12-31	Completed
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women[NCT01310023]		3,400 participants (Anticipated)	Observational	2007-03-31	Recruiting
A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744]	Phase 2	112 participants (Anticipated)	Interventional	2021-08-03	Recruiting
Structural Fat Grafting for Craniofacial Trauma: Repeat Fat Grafting Injection-5 Subject Cohort[NCT01822301]		5 participants (Actual)	Interventional	2013-04-30	Completed
Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection[NCT00959894]	Phase 2	80 participants (Actual)	Interventional	2009-09-30	Completed
Evaluation of Metabolic Complications Associated With Antiretroviral Medications in HIV-1-Infected Pregnant Women[NCT00017797]		160 participants	Observational		Completed
Assessing the Relationship Between Fatigue and Mitochondrial Toxicity in Patients With HIV/AIDS[NCT00106795]		82 participants (Actual)	Observational	2005-03-22	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

the facial volume and appearance grading scale evaluates each aesthetic region in the face based on both physical examination and 3D photography by the clinician. scale ranges from 1-3 where a score of 1 indicates an obvious contour defect; 2 shows a noticeable improvement in contour but not sufficient to impart a normal appearance; 3 represents a normal appearance and/or close approximation with a normal uninjured contralateral structure. (NCT01822301)
Timeframe: assessed at baseline (pre-op), days 7-21 post-op, 3 months post-op, and 9 months post-op

Serial Computed Tomography Imaging

Intervention	units on a scale (Mean)
Facial Volume Score at Baseline	1.8
Facial Volume Score at 7-21 Day PO	2.2
Facial Volume Score at 3 Month PO	2.2
Facial Volume Score at 9 Months PO	2.6

serial computed tomography images were collected to evaluate the volume of the defect (NCT01822301)
Timeframe: assessed at 7-21 days, 3 months and 9 months post op.

Change in CD4+ Cell Count From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	volume, mL (Mean)
CT Imaging at 7-21 Days PO	15
CT Imaging at 3 Months PO	10.3
CT Imaging at 9 Months PO	12.4

The per-protocol analysis of change in CD4+ cell count from baseline to Week 24 was calculated using the measurement closest to schedule and within the analysis window, and quantified with an estimated median and distribution-free 95% confidence interval (CI). (NCT00959894)
Timeframe: Baseline to 24 weeks

Change in CD4+ Cell Count From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	cells/uL (Median)
Etravirine 400 mg Once Daily	156

The per-protocol intention-to-treat analysis of change in CD4+ cell count from baseline to Week 48 was calculated using the measurement closest to schedule and within the analysis window, and quantified with an estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 48 weeks

Change in CD4+ Cell Count From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	cells/uL (Median)
Etravirine 400 mg Once Daily	163

The per-protocol intention-to-treat analysis of change in CD4+ cell count from baseline to Week 96 was calculated using the measurement closest to schedule and within the analysis window, and quantified with an estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 96 weeks

Change in Fat Mass Ratio as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	cells/uL (Median)
Etravirine 400 mg Once Daily	224

Change from baseline to follow-up in fat mass ratio was calculated. Whole body Dual X-ray Absorptiometry (DEXA) scans (Hologic Discovery W, Hologic Inc., Bedford, MA) were conducted at baseline, Week 24, and Week 96 to assess body fat distribution. Fat mass ratio was calculated as the ratio of trunk fat percentage and lower limb fat percentage (% trunk fat mass / % lower limb fat mass). Calculations of change from baseline to follow-up used the value closest to schedule and within the analysis window, and were quantified with the estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 24 weeks

Change in Fat Mass Ratio as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	ratio of trunk fat % : lower limb fat % (Median)
Etravirine 400 mg Once Daily	0.02

Change in Glucose Metabolism (Insulin Resistance), in a Subgroup of up to 40 Participants, From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	ratio of trunk fat % : lower limb fat % (Median)
Etravirine 400 mg Once Daily	0.06

Metabolic data analyses were conducted as-treated. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR), and was calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5. Changes from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 24 weeks

Change in Glucose Metabolism (Insulin Resistance), in a Subgroup of up to 40 Participants, From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	µU/ml*mmol/L (Median)
Etravirine 400 mg Once Daily	-0.08

Change in Glucose Metabolism (Insulin Resistance), in a Subgroup of up to 40 Participants, From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	µU/ml*mmol/L (Median)
Etravirine 400 mg Once Daily	0.71

Pharmacokinetics of Etravirine in Genital Secretions of up to 10 Men and up to 10 Women at Week 4 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	µU/ml*mmol/L (Median)
Etravirine 400 mg Once Daily	0.23

This secondary outcome measure assessed the ratio of semen:plasma concentration of etravirine in paired semen and plasma samples collected from 14 male participants at Week 4 of treatment with etravirine and fixed dose tenofovir/emtricitabine. (NCT00959894)
Timeframe: 4 weeks

Population Pharmacokinetics of Etravirine 400 mg Once Daily, in Combination With Fixed-dose Emtricitabine-tenofovir Among Treatment-naïve HIV-1 Infected Adults: Etravirine AUC-24 Hours at Steady State

Intervention	ratio of semen:plasma drug concentration (Median)
Etravirine 400 mg Once Daily	0.192

Population pharmacokinetics were calculated using sparse sampling. Plasma concentrations of etravirine measured in samples from participants who provided blood samples at multiple study visits, with variation in sampling times relative to dosing of etravirine used to cover the spectrum of the dosing schedule. Model simulations and fitting were performed with NONMEM ® 7.3. (ICON, plc) and model exploration was performed with Berkeley Madonna (Berkeley, CA, USA) (NCT00959894)
Timeframe: At or after 4 weeks

Probability of Remaining Free of a Safety/Tolerability Event at 96 Weeks

Intervention	ng*hr/mL (Median)
Etravirine 400 mg Once Daily	8024.40

The Kaplan-Meier method was used to estimate the proportion of participants ever exposed to etravirine who remained event-free through Week 96, with a 95% CI using Greenwood's variance estimate and a log-log transformation. Time was handled as continuous (weeks from treatment start to event or censoring). (NCT00959894)
Timeframe: 96 weeks

The Antiretroviral Activity of Etravirine 400 mg Given Once Daily, With Fixed-dose Truvada Once Daily, Among Treatment-naïve HIV-1 Infected Adults as Measured by the Percentage of Participants With HIV RNA < 50 Copies/mL at Week 24

Intervention	proportion of participants (Number)
Etravirine 400 mg Once Daily	0.69

The primary study endpoint was the proportion of participants who achieved HIV-1 RNA <50 copies/ml at Week 24 of study participation. The per-protocol primary analysis was conducted intention-to-treat, with missing evaluations counted as failures. Achievement of HIV-1 viral load below 50 copies/ml was defined as having HIV-1 RNA <50 copies/ml during the Week 24 analysis window (>18 and <30 weeks post-entry). (NCT00959894)
Timeframe: 24 weeks

The Proportion of Participants With HIV RNA <200 Copies/mL at Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	proportion of participants (Number)
Etravirine 400 mg Once Daily	0.87

This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <200 copies/ml at Week 24 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 24 weeks

The Proportion of Participants With HIV RNA <200 Copies/mL at Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	proportion of participants (Number)
Etravirine 400 mg Once Daily	0.89

This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <200 copies/ml at Week 48 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 48 weeks

The Proportion of Participants With HIV RNA <200 Copies/mL at Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	proportion of participants (Number)
Etravirine 400 mg Once Daily	0.82

This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA 200 copies/ml at Week 96 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 96 weeks

The Proportion of Participants With HIV RNA <50 Copies/mL at Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	proportion of participants (Number)
Etravirine 400 mg Once Daily	0.77

This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <50 copies/ml at Week 48 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 48 weeks

The Proportion of Participants With HIV RNA <50 Copies/mL at Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	proportion of participants (Number)
Etravirine 400 mg Once Daily	0.77

This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <50 copies/ml at Week 96 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 96 weeks

Change in Limb and Trunk Fat Distribution as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	proportion of participants (Number)
Etravirine 400 mg Once Daily	0.71

Changes from baseline to follow-up in limb fat, trunk fat, total body fat, and lean mass were calculated. Whole body Dual X-ray Absorptiometry (DEXA) scans (Hologic Discovery W, Hologic Inc., Bedford, MA) were conducted at baseline, Week 24, and Week 96 to assess body fat distribution. Calculations of change from baseline to follow-up used the value closest to schedule and within the analysis window, and were quantified with the estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 24 weeks

Change in Limb and Trunk Fat Distribution as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	percentage of body fat (Median)
	Total body fat	Limb fat	Trunk fat
Etravirine 400 mg Once Daily	0.43	0.48	0.32

Change in the Lipid Profile and Glucose Metabolism, in a Subgroup of up to 40 Participants, From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	percentage of body fat (Median)
	Total body fat	Limb fat	Trunk fat
Etravirine 400 mg Once Daily	1.44	0.82	1.93

Change in the Lipid Profile and Glucose Metabolism, in a Subgroup of up to 40 Participants, From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	mg/dL (Median)
	Total cholesterol	HDL-cholesterol	LDL-cholesterol	Triglycerides	Fasting glucose
Etravirine 400 mg Once Daily	-7	1	-9	-16	1

Change in the Lipid Profile and Glucose Metabolism, in a Subgroup of up to 40 Participants, From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Intervention	mg/dL (Median)
	Total cholesterol	HDL-cholesterol	LDL-cholesterol	Triglycerides	Fasting glucose
Etravirine 400 mg Once Daily	6	5	-1	-10	2

Metabolic data analyses were conducted as-treated. Changes in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and fasting blood glucose from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR), and was calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5. (NCT00959894)
Timeframe: Baseline to 96 weeks

Population Pharmacokinetics of Etravirine 400 mg Once Daily, in Combination With Fixed-dose Emtricitabine-tenofovir Among Treatment-naïve HIV-1 Infected Adults

Intervention	mg/dL (Median)
	Total cholesterol	HDL-cholesterol	LDL-cholesterol	Triglycerides	Fasting glucose
Etravirine 400 mg Once Daily	6	4	-5	3	2

Resistance Mutations in the Subset of Patients With Confirmed Virologic Failure Who Have HIV RNA >500 Copies/mL and Genotype Resistance Results

Intervention	ng/mL (Median)
	Etravirine trough plasma concentration	Etravirine peak plasma concentration
Etravirine 400 mg Once Daily	217.47	480.99

Per-protocol, genotype testing was conducted at confirmation of virologic failure if the confirmatory HIV-1 RNA was above the laboratory-specified threshold of 500 copies/mL. HIV-1 genotype was determined using the TRUGENE® HIV-1 assay (Siemens Healthcare Diagnostics, Tarrytown, NY) (NCT00959894)
Timeframe: 96 weeks

Tolerability of Etravirine in HIV-1 Infected Adults Initiating Antiretroviral Therapy

Intervention	participants (Number)
	Y181C	E138K	E138K, Y181C, M230L, M184I, K219E, V75I	No resistance-associated mutations detected
Etravirine 400 mg Once Daily	1	1	1	3

"The safety/tolerability endpoint was defined as the first grade 3 or higher sign, symptom or laboratory abnormality that was at least one grade higher than baseline among participants ever exposed to etravirine (regardless of treatment status), or permanent discontinuation of etravirine due to any toxicity (regardless of grade). Modification of tenofovir/emtricitabine was not a safety/tolerability event.~The Kaplan-Meier method was used to estimate the proportion of participants ever exposed to etravirine who remained event-free through Week 96, with a 95% CI using Greenwood's variance estimate and a log-log transformation. Time was handled as continuous (weeks from treatment start to event or censoring)." (NCT00959894)
Timeframe: 96 weeks

Article	Year
Vaginal microbiota and sexually transmitted infections that may influence transmission of cell-associated HIV. The Journal of infectious diseases, 2014, Dec-15, Volume: 210 Suppl 3 Topics: Female; HIV Infections; Humans; Lactic Acid; Lactobacillus; Leukocytes; Male; Microbiota; Sexually T	2014
Adverse drug reactions to antiretroviral medication. Frontiers in bioscience (Landmark edition), 2009, 01-01, Volume: 14, Issue:5 Topics: Anti-HIV Agents; Bone Diseases, Metabolic; Bone Marrow; Cardiovascular System; Drug Hypersensitivity	2009
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. Journal of acquired immune deficiency syndromes (1999), 2002, Nov-01, Volume: 31, Issue:3 Topics: Adipose Tissue; Anti-HIV Agents; Bone Diseases, Metabolic; Glucose; HIV Infections; HIV-1; Homeostas	2002
Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection. Current drug targets, 2003, Volume: 4, Issue:1 Topics: Acidosis, Lactic; Antiretroviral Therapy, Highly Active; Bone Diseases, Metabolic; DNA, Mitochondria	2003
Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors. Critical care (London, England), 2003, Volume: 7, Issue:3 Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Carnitine; HIV Infections; Humans; Lactic Acid; Mitochondr	2003
Poly-L-lactic acid. American journal of clinical dermatology, 2004, Volume: 5, Issue:5 Topics: Adipose Tissue; Biocompatible Materials; Delayed-Action Preparations; Dose-Response Relationship, Dr	2004
Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. Clinical nutrition (Edinburgh, Scotland), 2005, Volume: 24, Issue:1 Topics: Acidosis, Lactic; Anti-HIV Agents; HIV Infections; Humans; Lactic Acid; Nucleosides; Prevalence; Rev	2005
The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV/HCV-coinfected individuals. Antiviral therapy, 2005, Volume: 10 Suppl 2 Topics: Acidosis, Lactic; Anti-HIV Agents; Antiviral Agents; DNA Damage; DNA, Mitochondrial; Hepatitis C; HI	2005
Symptomatic hyperlactataemia and lactic acidosis in the era of highly active antiretroviral therapy. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2005, Volume: 95, Issue:12 Topics: Acidosis, Lactic; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lactic Acid; Revers	2005
Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies. International journal of STD & AIDS, 2006, Volume: 17, Issue:7 Topics: Clinical Trials as Topic; Face; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome	2006
Toxic metabolic syndrome associated with HAART. Expert opinion on drug metabolism & toxicology, 2006, Volume: 2, Issue:3 Topics: Adiponectin; Adipose Tissue; Animals; Antiretroviral Therapy, Highly Active; Bone Diseases, Metaboli	2006
Poly-L-lactic acid for facial lipoatrophy in HIV. The Annals of pharmacotherapy, 2006, Volume: 40, Issue:9 Topics: Face; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Injections, Subcutaneous	2006
Sculptra (injectable poly-L-lactic acid). Facial plastic surgery clinics of North America, 2007, Volume: 15, Issue:1 Topics: Adipose Tissue; Atrophy; Cellulose; HIV Infections; Humans; Injections, Subcutaneous; Lactic Acid; M	2007
Mitochondrial disorders among infants exposed to HIV and antiretroviral therapy. Drug safety, 2007, Volume: 30, Issue:10 Topics: Anemia; Animals; Anti-HIV Agents; Blood Cell Count; Developmental Disabilities; DNA, Mitochondrial;	2007
Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS (London, England), 2007, Nov-30, Volume: 21, Issue:18 Topics: Acidosis, Lactic; Adult; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Ly	2007

Article	Year
Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE]. HIV medicine, 2013, Volume: 14, Issue:7 Topics: Acrylic Resins; Adult; Aged; Anti-HIV Agents; Face; Female; HIV; HIV Infections; HIV-Associated Lipo	2013
Oral L-arginine modulates blood lactate and interleukin-6 after exercise in HIV-infected men. International journal of sports medicine, 2014, Volume: 35, Issue:4 Topics: Administration, Oral; Antiretroviral Therapy, Highly Active; Arginine; Dietary Supplements; Exercise	2014
Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study. AIDS research and human retroviruses, 2009, Volume: 25, Issue:10 Topics: Acrylic Resins; Adult; Aged; Drug-Related Side Effects and Adverse Reactions; Female; Gels; HIV Infe	2009
Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial. AIDS research and human retroviruses, 2012, Volume: 28, Issue:8 Topics: Acidosis, Lactic; Adult; Anti-Retroviral Agents; Botswana; Drug Therapy, Combination; Female; Follow	2012
Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. Critical care medicine, 2003, Volume: 31, Issue:4 Topics: Acidosis, Lactic; Adult; Antiviral Agents; Carnitine; Female; HIV Infections; Humans; Lactic Acid; M	2003
A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV medicine, 2004, Volume: 5, Issue:2 Topics: Administration, Cutaneous; Adult; Antiretroviral Therapy, Highly Active; Anxiety; CD4 Lymphocyte Cou	2004
Use of polylactic acid in face lipodystrophy in HIV positive patients undergoing treatment with antiretroviral drugs (HAART). Acta chirurgiae plasticae, 2004, Volume: 46, Issue:1 Topics: Adult; Antiretroviral Therapy, Highly Active; Biocompatible Materials; Face; Female; HIV Infections;	2004
Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. Journal of acquired immune deficiency syndromes (1999), 2005, Apr-01, Volume: 38, Issue:4 Topics: Adult; Antiretroviral Therapy, Highly Active; Facial Dermatoses; Female; Follow-Up Studies; HIV Infe	2005
Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study. Antiviral therapy, 2005, Volume: 10, Issue:6 Topics: Acrylic Resins; Adipose Tissue; Adult; Facial Dermatoses; Female; HIV Infections; HIV-Associated Lip	2005
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV medicine, 2006, Volume: 7, Issue:2 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; CD4 Lymphocyte Co	2006
Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/microL: a randomized trial. Journal of acquired immune deficiency syndromes (1999), 2006, Apr-01, Volume: 41, Issue:4 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Inf	2006
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). Journal of acquired immune deficiency syndromes (1999), 2007, Apr-15, Volume: 44, Issue:5 Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose;	2007
Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients. European journal of medical research, 2007, Feb-26, Volume: 12, Issue:2 Topics: Adenine; Adult; Aged; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Cholesterol; Cholesterol,	2007
Oral glucose loading for detection of mitochondrial toxicity during HAART in HIV-infected patients. Current HIV research, 2007, Volume: 5, Issue:4 Topics: Adult; Antiretroviral Therapy, Highly Active; Drug-Related Side Effects and Adverse Reactions; Femal	2007
Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy. Obstetrics and gynecology, 2007, Volume: 110, Issue:2 Pt 1 Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Cholesterol, HDL; Cohort Studies; Female;	2007
Point-of-care lactate testing predicts mortality of severe sepsis in a predominantly HIV type 1-infected patient population in Uganda. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Jan-15, Volume: 46, Issue:2 Topics: Adult; Female; HIV Infections; HIV-1; Humans; Lactic Acid; Male; Point-of-Care Systems; Predictive V	2008
Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Apr-15, Volume: 46, Issue:8 Topics: Adipose Tissue; Adult; Anti-HIV Agents; Body Composition; Bone Density; DNA, Mitochondrial; Female;	2008
Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS (London, England), 2000, Dec-01, Volume: 14, Issue:17 Topics: Acidosis, Lactic; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyt	2000
Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS (London, England), 2001, May-25, Volume: 15, Issue:8 Topics: Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; I	2001
High levels of lactic acid in some users of HAART. TreatmentUpdate, 2001, Volume: 13, Issue:1 Topics: Acidosis, Lactic; Adult; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Lact	2001

Article	Year
Distinct Immune Responses Elicited From Cervicovaginal Epithelial Cells by Lactic Acid and Short Chain Fatty Acids Associated With Optimal and Non-optimal Vaginal Microbiota. Frontiers in cellular and infection microbiology, 2019, Volume: 9 Topics: Anti-Inflammatory Agents; Chemokines; Cytokines; Epithelial Cells; Fatty Acids, Volatile; Female; HI	2019
Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. Mucosal immunology, 2017, Volume: 10, Issue:6 Topics: Anti-Inflammatory Agents; Cell Line; Cytokines; Epithelial Cells; Female; HIV; HIV Infections; Human	2017
A prominent lactate peak as a potential key magnetic resonance spectroscopy (MRS) feature of progressive multifocal leukoencephalopathy (PML): Spectrum pattern observed in three patients. Bosnian journal of basic medical sciences, 2017, Nov-20, Volume: 17, Issue:4 Topics: Adult; Aged; Biomarkers; HIV Infections; Humans; JC Virus; Lactic Acid; Leukemia, Lymphocytic, Chron	2017
A longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of use. BMC infectious diseases, 2013, Feb-20, Volume: 13 Topics: Adult; Anti-Retroviral Agents; Cellulose; Face; Female; HIV Infections; HIV-Associated Lipodystrophy	2013
Mitochondrial toxicity studied with the PBMC of children from the Chinese national pediatric highly active antiretroviral therapy cohort. PloS one, 2013, Volume: 8, Issue:2 Topics: Adenosine Triphosphate; Adolescent; Blotting, Western; Child; Child, Preschool; China; DNA, Mitochon	2013
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PloS one, 2013, Volume: 8, Issue:4 Topics: Adenine; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line; Cervix Uteri; Chemistry, Pharma	2013
Blood lactate in HIV-infected children on antiretroviral therapy in rural South Africa. The Pediatric infectious disease journal, 2014, Volume: 33, Issue:4 Topics: Anti-Retroviral Agents; Child; Female; HIV Infections; Humans; Hyperlactatemia; Lactic Acid; Male; P	2014
Portable lactate analyzer for measuring lactate in cerebrospinal fluid (CSF) and plasma - method-comparison evaluations. Arquivos de neuro-psiquiatria, 2014, Volume: 72, Issue:7 Topics: Adult; Female; HIV Infections; Humans; Lactic Acid; Male; Middle Aged; Point-of-Care Systems; Predic	2014
Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC infectious diseases, 2014, Sep-01, Volume: 14 Topics: Adult; CD4 Lymphocyte Count; Cellulose; Face; Female; France; HIV Infections; HIV-Associated Lipodys	2014
Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses. Vaccine, 2014, Oct-29, Volume: 32, Issue:47 Topics: AIDS Vaccines; CD8-Positive T-Lymphocytes; Cell Movement; Cells, Cultured; Chemokine CCL19; Cocultur	2014
Biodegradable Film for the Targeted Delivery of siRNA-Loaded Nanoparticles to Vaginal Immune Cells. Molecular pharmaceutics, 2015, Aug-03, Volume: 12, Issue:8 Topics: Carrageenan; Cell Differentiation; Cell Survival; Cells, Cultured; Dendritic Cells; Female; Genetic	2015
Raised Venous Lactate and Markers of Intestinal Translocation Are Associated With Mortality Among In-Patients With HIV-Associated TB in Rural South Africa. Journal of acquired immune deficiency syndromes (1999), 2015, Dec-01, Volume: 70, Issue:4 Topics: Adolescent; Adult; Bacterial Translocation; Female; HIV Infections; Humans; Lactic Acid; Male; Middl	2015
Implementation and Operational Research: Implementation of Multiple Point-of-Care Testing in 2 HIV Antiretroviral Treatment Clinics in South Africa. Journal of acquired immune deficiency syndromes (1999), 2016, Feb-01, Volume: 71, Issue:2 Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; CD4 Antigens; Creatinine; Female; Health Plan I	2016
Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission. Molecular pharmaceutics, 2015, Dec-07, Volume: 12, Issue:12 Topics: Animals; Anti-HIV Agents; Drug Carriers; Drug Combinations; Drug Delivery Systems; HIV Infections; H	2015
Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands. Biomaterials, 2016, Volume: 75 Topics: Administration, Intranasal; Administration, Oral; AIDS Vaccines; Animals; B-Lymphocytes; Cell Prolif	2016
Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:6 Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Disease Models, Animal; Emulsifying Agents;	2016
Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:7 Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Female; HIV Infections; HIV-1; Lactic Acid;	2016
Early Stage HIV Management and Reduction of Stavudine-Induced Hepatotoxicity in Rats by Experimentally Developed Biodegradable Nanoparticles. AAPS PharmSciTech, 2017, Volume: 18, Issue:3 Topics: Animals; Anti-HIV Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carriers; Dru	2017
Presentation, management, and outcomes of sepsis in adults and children admitted to a rural Ugandan hospital: A prospective observational cohort study. PloS one, 2017, Volume: 12, Issue:2 Topics: Adolescent; Adult; Anti-Bacterial Agents; Blood Glucose; Child; Child, Preschool; Cohort Studies; Fe	2017
Co-factors for abnormal lactate levels among persons with HIV disease at a tertiary HIV care setting in South India. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2008, Volume: 46, Issue:8 Topics: Acidosis, Lactic; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectiona	2008
Symptomatic hyperlactataemia in adults on antiretroviral therapy: a single-centre experience. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2008, Volume: 98, Issue:10 Topics: Acidosis, Lactic; Adult; Aged; Anti-Retroviral Agents; Cohort Studies; Female; HIV Infections; Human	2008
Mitochondrial toxicity in HIV type-1-exposed pregnancies in the era of highly active antiretroviral therapy. Antiviral therapy, 2009, Volume: 14, Issue:3 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Mitochondrial; Electron Transpor	2009
Treatment of facial lipoatrophy in HIV-infected patients. Prescrire international, 2008, Volume: 17, Issue:96 Topics: Adipose Tissue; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as To	2008
Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. Journal of virology, 2009, Volume: 83, Issue:21 Topics: Animals; Cell Line; Cervix Uteri; Disease Models, Animal; Female; HIV Infections; HIV-1; Humans; Hyd	2009
[Treatment of facial lipatrophy]. MMW Fortschritte der Medizin, 2009, Apr-30, Volume: 151, Issue:18 Topics: Adipose Tissue; Antiretroviral Therapy, Highly Active; Biocompatible Materials; Cheek; Durapatite; H	2009
Late-onset immune-mediated adverse effects after poly-L-lactic acid injection in non-HIV patients: clinical findings and long-term follow-up. Dermatology (Basel, Switzerland), 2009, Volume: 219, Issue:4 Topics: Adult; Aged; Biocompatible Materials; Cohort Studies; Cosmetic Techniques; Edema; Face; Female; Foll	2009
Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC infectious diseases, 2009, Dec-09, Volume: 9 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Carriers; Drug Combinations; Drug Compou	2009
Modified poly-L-lactic acid injection technique: safety and efficacy of "cross-fanning" in non-HIV-related facial atrophy. Annals of plastic surgery, 2010, Volume: 64, Issue:4 Topics: Atrophy; Biocompatible Materials; Cosmetic Techniques; Face; Health Surveys; HIV Infections; Humans;	2010
Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. The Journal of infectious diseases, 2010, Jul-01, Volume: 202, Issue:1 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Administration Schedu	2010
Quantification of cerebrospinal fluid lactic acid in the differential diagnosis between HIV chronic meningitis and opportunistic meningitis. Clinical chemistry and laboratory medicine, 2011, Volume: 49, Issue:5 Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Biomarkers; Child; Child, Preschool; Chron	2011
Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis. Antiviral therapy, 2011, Volume: 16, Issue:2 Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans;	2011
Fatal toxicity from symptomatic hyperlactataemia: a retrospective cohort study of factors implicated with long-term nucleoside reverse transcriptase inhibitor use in a South African hospital. Drug safety, 2011, Jun-01, Volume: 34, Issue:6 Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Hospital Mortality; Humans; Lactic A	2011
A comparison of lower genital tract glycogen and lactic acid levels in women and macaques: implications for HIV and SIV susceptibility. AIDS research and human retroviruses, 2012, Volume: 28, Issue:1 Topics: Animals; Disease Susceptibility; Female; Glycogen; HIV Antibodies; HIV Infections; HIV-1; Humans; La	2012
pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2011, Volume: 79, Issue:3 Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Cell Line; Cell Survival; Drug Carriers; Dru	2011
Zidovudine (AZT) overdose in a healthy newborn receiving postnatal prophylaxis. Clinical toxicology (Philadelphia, Pa.), 2011, Volume: 49, Issue:8 Topics: Acidosis; Alanine Transaminase; Anti-HIV Agents; Drug Overdose; HIV Infections; Humans; Infant, Newb	2011
Hyperlactatemia and in utero exposure to antiretrovirals: is the control group the clue? AIDS research and human retroviruses, 2012, Volume: 28, Issue:8 Topics: Acidosis, Lactic; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cohort Studi	2012
Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medications. The Pediatric infectious disease journal, 2011, Volume: 30, Issue:12 Topics: Adult; Anti-HIV Agents; Blood Chemical Analysis; Child; Child, Preschool; Female; HIV Infections; HI	2011
Macrocytosis is a predictor of resting lactate concentrations in persons on dideoxynucleoside therapy for HIV infection. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2012, Volume: 16, Issue:4 Topics: Adult; Anemia, Macrocytic; Anti-HIV Agents; Biomarkers; Cell Size; Dideoxynucleosides; Erythrocyte I	2012
Submicron-size biodegradable polymer-based didanosine particles for treating HIV at early stage: an in vitro study. Journal of microencapsulation, 2012, Volume: 29, Issue:7 Topics: Animals; Anti-HIV Agents; Cells, Cultured; Delayed-Action Preparations; Didanosine; Drug Evaluation,	2012
The role of nucleoside reverse transcriptase inhibitors usage in the incidence of hyperlactatemia and lactic acidosis in HIV/AIDS patients. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2012, Volume: 66, Issue:4 Topics: Acidosis, Lactic; Acquired Immunodeficiency Syndrome; Adult; CD4 Lymphocyte Count; Didanosine; Drug	2012
Injectable poly-L-lactic acid for human immunodeficiency virus-associated facial lipoatrophy: cumulative year 2 interim analysis of an open-label study (FACES). Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2012, Volume: 38, Issue:7 Pt 2 Topics: Adipose Tissue; Adult; Aged; Atrophy; Cosmetic Techniques; Female; HIV Infections; Humans; Injection	2012
Treatment of HIV associated facial lipoatrophy: 2012 update. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2012, Volume: 38, Issue:7 Pt 2 Topics: Adipose Tissue; Female; HIV Infections; Humans; Lactic Acid; Male; Polyesters; Polymers	2012
Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis. Antiviral research, 2012, Volume: 96, Issue:3 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Ca	2012
Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. AIDS research and human retroviruses, 2013, Volume: 29, Issue:5 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Cell Line; Cell Survival; Cyclop	2013
Hyperlactatemia and concurrent use of antiretroviral therapy among HIV infected patients in Uganda. African health sciences, 2012, Volume: 12, Issue:3 Topics: Acidosis, Lactic; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cross-Sectional Studi	2012
Mitochondrial DNA and nucleoside toxicity. The New England journal of medicine, 2002, Jul-18, Volume: 347, Issue:3 Topics: Anti-HIV Agents; Dideoxynucleosides; DNA, Mitochondrial; Drug Therapy, Combination; Drug-Related Sid	2002
Mitochondrial DNA and nucleoside toxicity. The New England journal of medicine, 2002, Jul-18, Volume: 347, Issue:3 Topics: Anti-HIV Agents; DNA; DNA, Mitochondrial; Drug-Related Side Effects and Adverse Reactions; Genetic M	2002
Mitochondrial DNA and nucleoside toxicity. The New England journal of medicine, 2002, Jul-18, Volume: 347, Issue:3 Topics: Anti-HIV Agents; Dideoxynucleosides; DNA; DNA, Mitochondrial; Drug-Related Side Effects and Adverse	2002
Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS (London, England), 2002, Jul-05, Volume: 16, Issue:10 Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Cross-Sectional Studies; Didanosine; Dideoxynucleosides; F	2002
Hyperlactatemia and lactic acidosis: should routine screening be considered? The AIDS reader, 2002, Volume: 12, Issue:8 Topics: Acidosis, Lactic; HIV Infections; Humans; Lactic Acid; Reverse Transcriptase Inhibitors	2002
Anaerobic threshold and random venous lactate levels among HIV-positive patients on antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999), 2002, Oct-01, Volume: 31, Issue:2 Topics: Adult; Anaerobic Threshold; Anti-HIV Agents; Exercise Test; Female; HIV Infections; Humans; Lactic A	2002
Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS (London, England), 2002, Nov-08, Volume: 16, Issue:16 Topics: Acidosis, Lactic; Cell Line; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2; DNA, Mitochon	2002
Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or causal disorder? Journal of acquired immune deficiency syndromes (1999), 2002, Nov-01, Volume: 31, Issue:3 Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; DNA Damage; DNA, Mitochondrial; Female; HIV Infe	2002
The case against Zerit. GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 2002, Volume: 16, Issue:10 Topics: HIV Infections; Humans; Insulin Resistance; Lactic Acid; Lipodystrophy; Mitochondria; Reverse Transc	2002
[Fatty liver and increased serum lactate in a woman with HIV]. Deutsche medizinische Wochenschrift (1946), 2003, Jan-17, Volume: 128, Issue:3 Topics: Abdominal Pain; Antiretroviral Therapy, Highly Active; Biopsy; Fatty Liver; Female; Hepatomegaly; HI	2003
Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients. HIV medicine, 2003, Volume: 4, Issue:1 Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Didanosine; Female; Follow-Up Studies; HIV Infections; Hum	2003
Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2003, Jan-21, Volume: 168, Issue:2 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; HIV Infections; Humans; L	2003
Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment. Antiviral therapy, 2002, Volume: 7, Issue:4 Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; Humans; L	2002
Venous and arterial blood lactate in HIV-infected patients. Antiviral therapy, 2002, Volume: 7, Issue:4 Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lactic Acid; Male; Middle Aged; Stavudine	2002
Lactic acidemia in infection with human immunodeficiency virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Apr-01, Volume: 36, Issue:Suppl 2 Topics: Acidosis, Lactic; HIV; HIV Infections; Humans; Lactic Acid; Outcome Assessment, Health Care; Reverse	2003
Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles. Journal of virology, 2003, Volume: 77, Issue:10 Topics: AIDS Vaccines; Animals; Gene Products, gag; HIV Antibodies; HIV Infections; Humans; Immunization; Im	2003
Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. Journal of medical virology, 2003, Volume: 70, Issue:4 Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; DNA, Mitochondrial; Drug Therapy, Combination; Female;	2003
Human immunodeficiency virus infection with human granulocytic ehrlichiosis complicated by symptomatic lactic acidosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Jun-15, Volume: 36, Issue:12 Topics: Acidosis, Lactic; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Ehrlichiosis; HIV Infectio	2003
Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. The Pediatric infectious disease journal, 2003, Volume: 22, Issue:9 Topics: Acidosis, Lactic; Adolescent; Age Distribution; Analysis of Variance; Anti-HIV Agents; Child; Child,	2003
Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. The Pediatric infectious disease journal, 2003, Volume: 22, Issue:9 Topics: Acidosis, Lactic; Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cohort Studies	2003
Matched case-control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapy. HIV medicine, 2003, Volume: 4, Issue:4 Topics: Acidosis, Lactic; Anti-HIV Agents; Case-Control Studies; Didanosine; Female; HIV Infections; Humans;	2003
Preanalytical handling of samples for measurement of plasma lactate in HIV patients. Scandinavian journal of clinical and laboratory investigation, 2003, Volume: 63, Issue:6 Topics: Acidosis, Lactic; Adult; Blood Preservation; Glycolysis; HIV Infections; Humans; Hydrogen-Ion Concen	2003
Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS (London, England), 2003, Nov-21, Volume: 17, Issue:17 Topics: Adipose Tissue; Adult; Antiretroviral Therapy, Highly Active; Biocompatible Materials; Drug Implants	2003
Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2004, Volume: 29, Issue:1 Topics: Adult; Anti-HIV Agents; DNA, Mitochondrial; Female; HIV Infections; HIV-1; Humans; Lactic Acid; Male	2004
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology (Baltimore, Md.), 2004, Volume: 39, Issue:2 Topics: Acidosis, Lactic; Adult; Cross-Sectional Studies; Didanosine; DNA, Mitochondrial; Female; Hepatitis	2004
Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Mar-01, Volume: 38 Suppl 2 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Mitochondrial; HIV Infections; Humans;	2004
13C-Methionine breath test detects liver mitochondrial impairment in HIV-infected patients with antiretroviral drug-related hyperlactatemia. Journal of acquired immune deficiency syndromes (1999), 2004, Apr-01, Volume: 35, Issue:4 Topics: Adult; Anti-HIV Agents; Breath Tests; Carbon Isotopes; Female; HIV Infections; Humans; Lactic Acid;	2004
Kinetics of lactate metabolism after submaximal ergometric exercise in HIV-infected patients. HIV medicine, 2004, Volume: 5, Issue:5 Topics: Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; Ergometry; Exercise; Female; HIV	2004
[Lactic acidosis in HIV-patients--diagnosis and treatment]. MMW Fortschritte der Medizin, 2004, Apr-26, Volume: 146 Spec No 1 Topics: Acid-Base Equilibrium; Acidosis, Lactic; Anti-HIV Agents; DNA Polymerase gamma; DNA Replication; DNA	2004
FDA approves treatment for facial fat loss. AIDS alert, 2004, Volume: 19, Issue:10 Topics: Adult; Face; Female; HIV Infections; Humans; Lactic Acid; Lipodystrophy; Male; Middle Aged; Polyeste	2004
Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics, 2004, Volume: 114, Issue:5 Topics: Alanine; Antiretroviral Therapy, Highly Active; Didanosine; Female; HIV Infections; HIV Seronegativi	2004
A neonate with macrosomia, cardiomyopathy and hepatomegaly born to an HIV-infected mother. European journal of pediatrics, 2005, Volume: 164, Issue:3 Topics: Adipose Tissue; Antiretroviral Therapy, Highly Active; Arginine; Asphyxia; Brain; Cardiomegaly; Card	2005
Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. Journal of the American Academy of Dermatology, 2005, Volume: 52, Issue:2 Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Biocompatible Materials; Cosmetic Techniques; Dr	2005
[Treatment of symptomatic hyperlactatemia and lactic acidosis in HIV+ patients under nucleoside reverse transcriptase inhibitors]. Medicina clinica, 2005, Jul-09, Volume: 125, Issue:6 Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Carnitine; HIV Infections; Humans; Lactic Acid; Male; Midd	2005
[Lactic acidosis following antiretroviral therapy]. Medicina clinica, 2005, Jul-09, Volume: 125, Issue:6 Topics: Acidosis, Lactic; Anti-HIV Agents; HIV Infections; Humans; Lactic Acid; Reverse Transcriptase Inhibi	2005
Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy. Journal of medical virology, 2005, Volume: 77, Issue:1 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Mitochondrial; Gene Deletion; HI	2005
Muscle and liver lactate metabolism in HAART-treated and naive HIV-infected patients: the MITOVIR study. Antiviral therapy, 2005, Volume: 10, Issue:4 Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Female; HIV Infections;	2005
Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Sep-01, Volume: 41, Issue:5 Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans;	2005
13C-methionine breath test detects distinct hepatic mitochondrial dysfunction in HIV-infected patients with normal serum lactate. Journal of acquired immune deficiency syndromes (1999), 2005, Oct-01, Volume: 40, Issue:2 Topics: Adult; Breath Tests; Carbon Isotopes; Cross-Sectional Studies; DNA, Mitochondrial; Female; HIV Infec	2005
The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Nov-01, Volume: 41, Issue:9 Topics: Adult; Fasting; Female; HIV Infections; Humans; Insulin Resistance; Lactic Acid; Male; Reverse Trans	2005
Effects of highly active antiretroviral therapy on paediatric metabolite levels. HIV medicine, 2006, Volume: 7, Issue:1 Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cholest	2006
Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population. HIV medicine, 2006, Volume: 7, Issue:1 Topics: Absorptiometry, Photon; Adult; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active	2006
Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naïve patients. HIV medicine, 2006, Volume: 7, Issue:1 Topics: Adult; Aged; Anti-HIV Agents; Biomarkers; DNA, Mitochondrial; Drug Monitoring; Female; HIV Infection	2006
Noninvasive diagnosis of mitochondrial dysfunction in HAART-related hyperlactatemia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Feb-15, Volume: 42, Issue:4 Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; DNA, Mitochondrial; Electron Transport Comp	2006
Glucose production, oxidation and disposal correlate with plasma lactate levels in HIV-infected patients on HAART. The Journal of infection, 2007, Volume: 54, Issue:1 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Glucose; Glucose Clamp Technique; Glu	2007
Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy. Archives of dermatology, 2006, Volume: 142, Issue:3 Topics: Adult; Aged; Anti-Retroviral Agents; Biocompatible Materials; Drug Therapy, Combination; Face; Femal	2006
Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy. Clinical chemistry, 2006, Volume: 52, Issue:6 Topics: Anti-HIV Agents; Base Sequence; Blood Platelets; Cell Nucleus; Cells, Cultured; Didanosine; DNA, Mit	2006
[Hyperlactacidemia during antiretroviral therapy: frequency and clinical-therapeutic correlations]. Le infezioni in medicina, 2006, Volume: 14, Issue:1 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Comorbidity; Dy	2006
Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hépatites Virales 1209 study, Abidjan, Ivory Coast. Pediatrics, 2006, Volume: 118, Issue:4 Topics: Adult; Anti-Retroviral Agents; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infec	2006
Sensitivity of non-clade B primary HIV-1 isolates to mildly acidic pH. Journal of acquired immune deficiency syndromes (1999), 2006, Dec-01, Volume: 43, Issue:4 Topics: Acrylic Resins; Administration, Intravaginal; Anti-HIV Agents; Cell Line; Female; HIV Infections; HI	2006
Limitation of exercise capacity in nucleoside-treated HIV-infected patients with hyperlactataemia. HIV medicine, 2007, Volume: 8, Issue:2 Topics: Antiretroviral Therapy, Highly Active; Blood Volume; Cardiac Output; Exercise; Exercise Test; Exerci	2007
Metabolic complications of HIV therapy. IAPAC monthly, 2006, Volume: 12, Issue:9 Topics: Acidosis, Lactic; Anti-HIV Agents; Bone Diseases; Dyslipidemias; HIV Infections; Humans; Insulin Res	2006
Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy. Archives of neurology, 2007, Volume: 64, Issue:9 Topics: Adult; AIDS Dementia Complex; Antiretroviral Therapy, Highly Active; Aspartic Acid; Atrophy; Biomark	2007
Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Aug-15, Volume: 45, Issue:4 Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lactic Acid; Lamivudine; M	2007
[Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy]. Revue de stomatologie et de chirurgie maxillo-faciale, 2007, Volume: 108, Issue:6 Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Biocompatible Materials; Body Mass I	2007
New techniques for imaging Human Immunodeficiency Virus associated cognitive impairment in the era of highly active antiretroviral therapy. Archives of neurology, 2007, Volume: 64, Issue:9 Topics: Antiretroviral Therapy, Highly Active; Biomarkers; Cognition Disorders; Diffusion Magnetic Resonance	2007
Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2008, Volume: 12, Issue:6 Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans;	2008
Redox potential status in children with perinatal HIV-1 infection treated with zidovudine. AIDS (London, England), 1995, Volume: 9, Issue:12 Topics: 3-Hydroxybutyric Acid; Acetoacetates; Child; Child, Preschool; Female; HIV Infections; HIV-1; Humans	1995
Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS (London, England), 2001, Apr-13, Volume: 15, Issue:6 Topics: Absorptiometry, Photon; Acidosis, Lactic; Adult; Anti-HIV Agents; Body Composition; Body Weight; Bon	2001
Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS (London, England), 2001, Apr-13, Volume: 15, Issue:6 Topics: Acidosis, Lactic; Adult; Antiretroviral Therapy, Highly Active; Chronic Disease; Data Interpretation	2001
Management of hyperlactatemia: no need for routine lactate measurements. AIDS (London, England), 2001, Apr-13, Volume: 15, Issue:6 Topics: Acidosis, Lactic; Anti-HIV Agents; HIV Infections; Humans; Lactic Acid; Mitochondria; Monitoring, Ph	2001
[Symptomatic hyperlactemia in patients infected with the human immunodeficiency virus treated with nucleoside analogs]. Medicina clinica, 2001, Jun-09, Volume: 117, Issue:1 Topics: Adult; Anti-HIV Agents; Didanosine; Female; HIV Infections; HIV Reverse Transcriptase; Humans; Lacti	2001
Of power plants and energy shortages. TreatmentUpdate, 2001, Volume: 13, Issue:1 Topics: Acidosis, Lactic; Anti-HIV Agents; HIV Infections; Humans; Lactic Acid; Mitochondria; Reverse Transc	2001
Bone damage--more than just nukes involved. TreatmentUpdate, 2001, Volume: 13, Issue:1 Topics: Acidosis, Lactic; Anti-HIV Agents; Bone Resorption; HIV Infections; Humans; Lactic Acid; Life Style;	2001
Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Dec-15, Volume: 33, Issue:12 Topics: Adult; Anti-HIV Agents; HIV Infections; Humans; Lactic Acid; Male; Middle Aged; Reverse Transcriptas	2001
Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Feb-15, Volume: 34, Issue:4 Topics: Acidosis, Lactic; Adult; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lactic Acid;	2002
New information sheds light on the lactemia often associated with HAART therapy. HIV clinician, 2001,Fall, Volume: 13, Issue:4 Topics: Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lactic Acid	2001
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. The New England journal of medicine, 2002, Mar-14, Volume: 346, Issue:11 Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; DNA; DNA, Mitochondrial; Drug Therapy, Combination; Drug	2002
Hyperlactatemia syndromes in people with HIV infection. Current opinion in infectious diseases, 2002, Volume: 15, Issue:1 Topics: Acidosis, Lactic; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; HIV Infections; Homeostas	2002
Assessing nuke toxicity. TreatmentUpdate, 2002, Volume: 14, Issue:3 Topics: Case-Control Studies; CD4 Lymphocyte Count; DNA, Mitochondrial; HIV Infections; HIV Seronegativity;	2002

lactic acid and HIV Infections